ADIPOQ and metabolic dysfunction-associated steatotic liver disease: Additionally, adiponectin, an adipokine that is known to reduce insulin resistance and inflammation, is downregulated in NAFLD and is responsible for the progression of NAFLD to NASH and also to the development of CVD in patients of NAFLD [17].